Class I histone deacetylase inhibitor 4SC-202 exerts its anti-cervical cancer effects by targeting the prolactin receptor (PRLR) signaling pathway, thereby suppressing cancer cell proliferation and promoting cancer cell apoptosis. This evidence concerns the gene PRLR and cervical carcinoma.